Recent cross-sectional, population-based echocardiographic studies show that about half of all patients with heart failure have preserved left ventricular systolic function (HF-PSF). Cohort studies of hospitalized patients show a smaller proportion of HF-PSF. Compared to those with reduced systolic function, patients with HF-PSF are more often female, older, less likely to have coronary artery disease, and more likely to have hypertension. Patients with HF-PSF are less symptomatic and receive different pharmacologic therapy than patients with reduced systolic function. Morbidity and mortality rates in patients with HF-PSF are high but not quite as high as in patients with reduced systolic function. Though much has recently been learned about the syndrome of HF-PSF, many questions remain to be answered, not least how it should be treated. (J Am
INCIDENCE OF HF-PSF
There are only two studies of incident cases of CHF differentiating between preserved or reduced systolic function (9, 10) . In the Olmsted County study, 216 patients with new CHF presenting during the calendar year 1991 were identified (5) . Of these, 137 (63%) had a recent echocardiographic assessment of LV ejection fraction (LVEF), 59 (43%) of whom had PSF (LVEF Ն50%). Five had significant valve disease-that is, 54 (39%) had PSF and no valve disease. Patients with PSF were more often female (69% vs. 41%), more likely to have been diagnosed as an out-patient than an in-patient (86% vs. 71%), and older (78 vs. 74 years). Coronary heart disease (CHD) (31% vs. 53%), electrocardiographic (ECG) evidence of myocardial infarction (MI) (15% vs. 42%), radiographic cardiomegaly, and pulmonary edema were all less common in patients with PSF. Atrial fibrillation (AF) was more frequent (29% vs. 24%), whereas renal dysfunction (serum creatinine Ն1.3 mg/dl) was less common (37% vs. 51%) in patients with PSF.
In the Bromley CHF study, all local primary care physicians were asked to refer new cases of CHF to a special clinic; all local patients admitted to hospital with CHF were also identified (10) . Of the 332 new cases of CHF detected between February 1996 and April 1997, 310 (93%) had an echocardiogram: 16% of patients were found to have PSF; 68% a "mild to moderate" reduction in LV systolic function; and 16% severe LV systolic dysfunction on qualitative assessment. The PSF and LV systolic dysfunction groups were not compared.
Three factors may explain the discrepancy between these two studies. First, the Bromley study included 54 cases where CHF had developed after acute MI, likely increasing the proportion with reduced systolic function. Second, the "threshold" for differentiating PSF from "reduced" systolic dysfunction, which is critical in determining the proportion with systolic dysfunction (see following text), may have differed between the studies. Third, two biases may have occurred. Only 63% of patients in the Olmsted County study had an echocardiogram, compared to 93% in the Bromley study. In the Bromley study, 208 of the 332 cases (63%) were identified during hospital admission; these cases may be more likely to have reduced LV systolic function. Prevalence studies show better agreement than the incidence studies.
PREVALENCE OF HF-PSF
Cross-sectional population echocardiographic studies. We identified 10 such studies, 1 confined to Native Americans (Table 1) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The number of individuals screened and their age range varied widely. The means of identification of "CHF" also varied, from clinical examination by a single investigator to the use of an epidemiological questionnaire (e.g., Framingham score). The definition of PSF ranged from qualitative assessment of LVEF to quantitative measurement of fractional shortening (FS), a wall motion score or LVEF; FS was used most frequently but has certain limitations (see the following text). Table 1 and Figure 1 summarize the findings of the 10 studies.
The prevalence of both types of CHF increased with age. The proportion of patients with PSF ranged from 40% to 71% (with a mean of 56%) and was probably influenced by the method used to assess LV systolic function and the threshold dividing "preserved" from "reduced." For example, FS measures systolic function at the base of the heart and can be normal in patients with apical hypokinesis (whereas LVEF may be reduced). Regarding "threshold," comparison of the Copenhagen (13) and Västeras (14) studies shows that very different proportions of PSF may be calculated depending upon whether a left ventricular wall motion index (LVWMI) of Ͼ1.5 or Ͼ1.7 is used as the cut-point (see also FS in the Rotterdam (12) and Helsinki (16) studies and EuroHeart Failure survey later) ( Table 1 ). In the Cardiovascular Health Study (CHS), 80% of patients had an LVEF Ͼ0.45, but only 55% had an LVEF Ͼ0.55 (18) . There is no simple binary division between "preserved" and "reduced" systolic function. Instead, there is a "border zone" or "gray area" where there is uncertainty. Some investigators may define these patients as having preserved systolic function and others as having mildly reduced systolic function (Fig. 2) .
Only three studies cite separate prevalence figures for men and women. The proportion of women with HF-PSF exceeds that of men in all three studies. A case-control study from Framingham is consistent with this conclusion (3) . In that study, 73% of 33 women but only 33% of 40 men with CHF had PSF (also see the EuroHeart Failure survey later).
Though not strictly epidemiological studies, both the Improvement Programme in Evaluation and Management of Heart Failure (IMPROVEMENT-HF) (21) study, undertaken in primary care in 15 member countries of the European Society of Cardiology, and the Italian Network on Congestive Heart Failure (IN-CHF) study (22) , conducted in out-patients between 1995 and 1999 in 133 of the 192 Italian cardiology centers, are in close agreement with the findings summarized earlier.
Indices of diastolic function. Though often considered synomonous with CHF owing to diastolic dysfunction (DD), these two syndromes are not identical. There is the obvious minority of patients with significant valvular disease (and these have been poorly defined in most of the studies reviewed). Less obvious may be other causal mechanisms such as intermittent myocardial ischemia and AF (23, 24) . It is, therefore, of interest to know whether there is evidence of DD in patients with PSF. Four of the population echocardiographic studies have also reported indices of DD. In the CHS, mean atrial flow, early flow, and the ratio of early/ atrial flow (E/A ratio) did not differ between patients with HF-PSF and those with CHF and reduced systolic function (18) . Patients with HF-PSF had increased systolic wall thickness compared to those with reduced systolic function.
In the Helsinki Ageing Study, there was no difference in E/A ratio, isovolumic relaxation time (IVRT), LV mass, or LV hypertrophy between patients with PSF and those with reduced systolic function, though all of these measures differed between patients with CHF and subjects without (16) .
In the study from Asturias, all 10 patients with HF-PSF had Doppler evidence of DD (11) . In eight patients this was an IVRT Ͼ110 ms, and in the other two an abnormal mitral valve E deceleration time (DT) was the cause. Eight of the 10 patients also had echocardiographic LV hypertrophy.
Two extensive studies of DD in the general population have recently been reported (20, 24) . In 2,042 randomly selected residents of Olmsted County, Minnesota (20) , aged Ն45 years, the prevalence of symptomatic CHF was measured using the Framingham criteria, and systolic and diastolic LV function was assessed by Doppler echocardiography. The prevalence of CHF was 2.2%; 20.8% of the population had mild, 6.6% moderate, and 0.7% severe DD; 6% had an LVEF Յ50%, and 2% an LVEF Յ40%; CHF was more frequent in those with systolic or diastolic dysfunction, although even in subjects with moderate or severe ventricular dysfunction of either type, fewer than half of them had CHF (Fig. 3 ). There was a considerable overlap between systolic and DD (e.g., the prevalence of moderate or severe DD in subjects with an LVEF Յ50% was 35.2%). Conversely, in subjects with mild, moderate, or severe DD, 10.5%, 19.5%, and 61.5%, respectively, had an LVEF Յ50%. "Isolated DD" was also common; that is, the prevalence of moderate or severe DD in subjects with an LVEF Ͼ50% was 5.9%. Interestingly, DD was as prevalent in men as in women.
In the second study (24) , the prevalence of DD was measured in 1,274 men and women age 27 to 75 years (mean 51 years) in Augsburg, Germany. The criteria advocated by the European Study Group on Diastolic Heart Failure were used to measure DD (25) . Some 2.3% of the population had an LVEF Ͻ45%. Of the remainder, 11.1% fulfilled the European criteria for DD. *Fifty-one patients with valve disease were excluded. †Normal (LVEF Ն55%); mild (LVEF 45%-54%), moderate (LVEF 30%-44%) or severe (LVEF Ͻ30%) dysfunction. ‡A total of 4.9% when value disease is excluded. a) ϭ data from reference 18; b) ϭ data from reference 44. CHF ϭ chronic heart failure; CHS ϭ Cardiovascular Health Study; EPICA ϭ Epidemiologia da Insuficîencia Cardiaca e Aprendiazagem; ESC ϭ European Society of Cardiology; FS ϭ fractional shortening; LV ϭ left ventricular; LVEF ϭ left ventricular ejection fraction; LVWMI ϭ left ventricular wall motion index; SHS ϭ Strong Heart Study. individuals (i.e., those without cardiac disease, hypertension, etc.) was 4.3%. Diastolic dysfunction was more common in men (13.8%) than in women (8.6%, p Ͻ 0.01), in keeping with the Olmsted County Study: 3.1% of subjects had more severe DD, defined as DD associated with either left atrial enlargement or diuretic treatment. These new studies tell us that Doppler evidence of DD is common in the general population (even more so than systolic dysfunction), is often asymptomatic, and adversely affects prognosis. Paradoxically, DD is more common in men, despite the predominance of women with HF-PSF. Hospitalization cohorts. We have identified 12 such studies published since January 2000 (Table 2 ) (26 -37). They are heterogeneous, ranging from small single-center studies with a majority of African American patients, through a large sample of Medicare beneficiaries in the United States, to a countrywide epidemiological survey from France. Most have incomplete information on assessment of LV function. The proportion of patients with PSF was less than in population studies, ranging from 24% to 55% (mean 41%), consistent with the evidence that patients with CHF and PSF have less severe symptoms and are less likely to require in-patient treatment (see subsequent text).
Patients with PSF were less likely to have had a prior history of, or hospitalization for, CHF. As in the population studies, there was a clear preponderance of females, and Masoudi et al. (34) confirmed in a multivariate analysis that female gender was an independent predictor of PSF in patients with CHF. The recent Euro Heart Failure survey of 11,327 hospital discharges from 115 hospitals in 24 European countries supports these findings (Fig. 4) (38) . Only 28% of women with CHF had an LVEF of Ͻ0.40, compared to 51% of men. Patients with PSF were also older, though the relationship between age and PSF appears to be less strong than that between PSF and female gender (34) .
SYMPTOMS, SIGNS, QUALITY OF LIFE, OTHER INDICES OF MORBIDITY, AND HOSPITAL STAY
In two studies, the frequency of characteristic symptoms (dyspnea at rest and on exercise; orthopnea) and signs (elevated jugular venous pressure, pedal edema, and pulmo- nary crackles) was similar in patients with PSF and reduced systolic function (though both these studies enrolled mainly African Americans (27, 33) . The exception was a third heart sound that was less frequent in PSF. In four studies, radiographic cardiomegaly was less common in patients with PSF. The (IN-CHF) study supports this finding, showing that patients with PSF have smaller echocardiographic LV dimensions in diastole and systole (22) . Philbin et al. (26) and Varela-Roman et al. (31) found that patients with PSF are less likely to be in a higher New York Heart Association (NYHA) class, a finding confirmed in the IN-CHF study (22) . Smith et al. (35) recently reported that severe dyspnea was less common in patents with PSF. Philbin et al. (26) also measured quality of life (QoL) using the ladder of life score (maximum score 10 ϭ perfect health). The mean score was 6.5 in patients with reduced systolic function and 6.4 in those with PSF, scores almost identical to those in another study of a clinic cohort, using the same QoL instrument (39) . In a more recent study (6) , however, both a general QoL instrument (the Short Form 36) and disease-specific one (the Minnesota Living With Heart Failure Questionnaire) showed greater reductions in QoL in patients with reduced LV systolic function than in those with PSF (though both groups of patients had a lower QoL than expected for the general population).
Other insights into the morbidity can be gleaned from the studies summarized in Table 2 . The mean Charlson co-morbidity index was 2.8 and 2.9 in the preserved and reduced systolic function groups, respectively, in the study by Philbin et al. (26) . Smith et al. (35) found that patients with reduced systolic function had limitation of a greater number of daily living activities.
Ahmed et al. (29) found that 6% of both groups of patients had been admitted from a nursing home, and Philbin et al. (26) reported this proportion to be 13% in the PSF group and 10% in the reduced systolic function group.
In the four studies reporting length of hospital stay, there was little difference between the two types of CHF. For the preserved and reduced systolic function groups, respectively, the durations of stay were 11 versus 11 days (French study), 7.5 versus 7.9 days (Philbin et al.), 6.1 versus 7.0 days (Dauterman et al.), and 5.2 versus 5.9 days (Malki et al.) (26 -28,30) . In a more detailed analysis, both Philbin et al. and Malki et al. noted that length of stay tended to increase with decreasing LVEF (26, 27) . Presumably, the powerful effect of age offsets this effect when patients are dichotomized into preserved and reduced LV systolic function groups (the former group being older on average).
CONCOMITANT MEDICAL PROBLEMS
Few of the population-based echocardiographic studies provide details on co-morbidity and medical therapy, but more is provided by the hospitalization cohort studies (Table 3) .
Myocardial infarction (or any evidence of CHD) was much less common in patients with PSF than in those with reduced systolic function (though more common in patients with HF-PSF than in age-and gender-matched controls) (3). Other evidence of atherosclerotic disease (peripheral arterial/cerebrovascular) was also less common. The IN-CHF registry reported similar findings (22) . In a multivariate analysis, Masoudi et al. (34) found that CHD was an independent predictor of a lower risk of finding PSF in patients hospitalized with CHF.
Conversely, hypertension (and a suspected hypertensive etiology) was more common in patients with PSF (40, 41) . The IN-CHF study also supports this finding (22) . In a multivariate analysis, Masoudi et al. (34) were also able to confirm that a history of hypertension was an independent predictor of PSF in patients hospitalized with CHF.
Both of these co-morbidities showed considerable geographical/ethnic variation. Hypertension was considered the etiology in about a third of Japanese patients but only 16% in the predominantly white U.S. patients studied by Philbin et al. (26) . Hypertension appeared to be particularly common in Native Americans with PSF (19) . Left ventricular Figure 3 . Prevalence of heart failure in subjects in the general population with left ventricular systolic and diastolic dysfunction (Olmsted County Study, Minnesota). CHF ϭ chronic heart failure. *Number with LVEF measurement (total number in cohort); it is unclear whether entire cohort had an LVEF measurement. †In years. ‡Nonwhite. §Non-Caucasian. 75% overall. AA ϭ African American; ACE-I ϭ angiotensin-converting enzyme inhibitor; CHF ϭ chronic heart failure; C/I ϭ contraindication; CXR ϭ chest X-ray; DRG ϭ diagnosis-related group; Echo ϭ echocardiographic; ESC ϭ European Society of Cardiology; LV ϭ left ventricular; LVEF ϭ left ventricular ejection fraction; MISCHF ϭ Management to Improve Survival in Congestive Heart Failure; P/R ϭ preserved/reduced LV systolic function; RNVG ϭ radionuclide ventriculogram; WMI ϭ wall motion index.
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hypertrophy was also more common in patients with PSF (the exception is the study by Thomas et al. [33] ).
The incidence of AF was also more frequent in subjects with PSF and, overall, was remarkably common in this patient subset (occurring in a quarter to a third of patients). In the IN-CHF registry, 16% of low LVEF patients had AF, compared to 25% of patients with an LVEF Ͼ45% (22) . In a multivariate analysis, Masoudi et al. (34) showed that AF was an independent predictor of a higher risk of PSF in patients hospitalized with CHF. This raises the question of whether AF is the primary cause of CHF in patients with PSF, rather than a secondary problem (23, 34) .
Diabetes mellitus was also common in both types of CHF. However, apart from the Strong Heart Study (19) , this co-morbidity was not more frequent in patients with PSF, despite prior speculation that diabetes may be a risk factor for DD (though Redfield et al. [20] found that diabetes did seem to be associated with an increased prevalence of DD). Moreover, chronic lung disease was more common in patients with PSF, raising the concern of misdiagnosis (42) .
There was also no clear difference in the frequency of renal impairment, creatinine concentration, or creatinine clearance between the two patient groups. This may appear odd, given the older average age in the PSF cohort. However, renal blood flow and renal function may be depressed more in patients with reduced systolic function, and use of angiotensin-converting enzyme (ACE) inhibitors is greater in these patients.
MEDICAL TREATMENT
Use of ACE inhibitors and digoxin was employed less frequently in patients with PSF, as might be expected, though the rate of use of both types of medication varied greatly between studies (Table 3) . Beta-blocker use was greater in the PSF group, although these studies, generally, predate the recent evidence for this treatment in patients with reduced LV systolic function. The findings of the IMPROVEMENT-HF study (21) and the IN-CHF registry (22) are consistent with the above studies.
Calcium channel blocker use was much greater in patients with PSF, reflecting the view that these agents may be of benefit in this type of CHF (and that they are harmful in reduced systolic function) (43) . In the IN-CHF registry, 23% of patients with an LVEF Ͼ45% were taking a calcium channel blocker compared to 8% of low-LVEF patients (22) .
ECONOMIC CONSIDERATIONS
There are few formal cost studies dealing with the problem of HF-PSF. However, some crude estimate of cost can be inferred from the rate of hospitalization, which accounts for most of the overall cost of CHF to health care systems. This is primarily driven by length of stay. Approximately 40% of patients hospitalized with CHF have PSF, and they have the same length of stay as those with reduced systolic function (see previous text). Consequently, 40% of the overall cost of CHF is probably accounted for by patients with PSF (though some expensive procedures are used less in patients with PSF). Support for this conclusion comes Figure 4 . Distribution of left ventricular ejection fraction measured within 12 months of the survey among women (n ϭ 2,048; 41% of total enrolled) and men (n ϭ 3,249; 57% of total enrolled) enrolled in the EuroHeart Failure survey. Where more than one ejection fraction measurement was available, the most recent one was used. Fifty-one percent of men but only 28% of women had a left ventricular ejection fraction Ͻ40%. --*ECG diagnosis. †Variably defined. ‡Comparison of patients with heart failure and not controls. §Patients without atrial fibrillation. Causes of heart failure. ACE-I ϭ angiotensin-converting enzyme inhibitor; AF ϭ atrial fibrillation; CCB ϭ calcium channel blocker; CHD ϭ coronary heart disease; CHS ϭ Cardiovascular Health Study; COPD ϭ chronic obstructive pulmonary disease; CVD ϭ cerebrovascular disease; MI ϭ myocardial infarction; PAD ϭ peripheral arterial disease; P/R ϭ preserved/reduced left ventricular systolic function; SHS ϭ Strong Heart Study.
from Philbin et al., where the mean hospital charge for both types of patient was approximately $8,600 (26) .
PROGNOSIS: MORTALITY
Population-based epidemiological studies. Two of the population-based prevalence studies reported prognosis (the Framingham case-control study also reports outcomes) (3). In the Helsinki Ageing Study, four-year mortality in individuals free of CHF was 30% (16) . Of those with CHF, the mortality rate was 43% among subjects with PSF and 54% in those with reduced systolic function (46% in patients with any CHF). In the Cardiovascular Health Study (CHS), the 6.4-year mortality rate in subjects without CHF was 16% compared to 45% in those with CHF (44) . The mortality rate in subjects without CHF and with PSF was 25 deaths per 1,000 patient-years. This rate rose to 87 in subjects with CHF and PSF, 115 in those with CHF and borderline systolic function, and 154 per 1,000 patient-years in subjects with CHF and reduced systolic function. These figures compare to an overall five-year mortality rate of 65% in the Olmsted County incidence study (9) . In that investigation, age-and gender-adjusted mortality rates were higher than in individuals free of CHF, though survival was not significantly different between patients with and without reduced systolic function. Patients with CHF in the Framingham Heart Study with reduced LV systolic function had an annual mortality rate of 18.9% compared to 4.1% in ageand gender-matched controls (over 6.2 years) (3). In patients with PSF, the annual mortality rate was 8.7% compared to 3% in their matched controls. In an adjusted analysis, patients with both types of CHF had four times the risk of death of their age-and gender-matched controls (3). The median survival in patients with reduced systolic function was 4.3 years, and it was 7.1 years in those with HF-PSF.
Notably in the CHS, the population-attributable mortality risk was greater for those with HF-PSF (7.5%) than for CHF with reduced systolic function (5.9%). This is explained by the higher prevalence (combined with moderate risk) of HF-PSF, compared to the lower prevalence of CHF with reduced systolic function (but at higher risk), in the elderly population studied (44) . Redfield et al. (20) recently described the prognostic importance of DD in the population. Mortality increased as the degree of DD increased, an effect independent of age, gender, and LVEF. In a multivariate analysis, compared to normal diastolic function, mild DD increased the risk of death 8.3-fold (p Ͻ 0.001) and moderate to severe DD increased this risk 10.2-fold (p Ͻ 0.001). Hospital cohort studies. Nine of the 12 hospital cohort studies identified report mortality, with follow-up periods ranging from six months to eight years (the French hospital survey also describes in-patient mortality rates) (26 -37) . It is not clear whether all these studies calculated mortality in the same way, that is, whether these include only postdischarge deaths or both in-patient (postadmission) and postdischarge deaths. Figure 5 shows the mortality rates from these studies (and two earlier ones), assuming these were calculated from admission. Patients with PSF have a better survival at all time points from admission. Nevertheless, patients with PSF still have a high mortality following admission to hospital, with rates of 40% to 50% after four to five years. The annual death rate in these studies agrees closely with that in the Framingham Heart Study (3). Gustafsson et al. (36) also showed that survival decreases as LV systolic function decreases in a graded way.
The IN-CHF registry has also reported one-year outcome data for out-patients with CHF (22) . One-year mortality was 18.8% in patients with an LVEF Ͻ35% (Group 1), 8.9% in patients with an LVEF Ͼ45% (Group 2), and 11.5% in patients with an LVEF between 35% and 45% (Group 3). Though survival was better in these ambulatory patients compared to hospitalized ones, the differential mortality effect was still apparent. Notably, an LVEF Ͻ35% (compared to an LVEF Ͼ45%) was an independent predictor of survival at one year.
PROGNOSIS: HOSPITAL ADMISSSIONS
Population-based studies. The risk of hospitalization was quantified in the Olmsted County incident case study (9) . Of patients with reduced LV systolic function, 10% were never hospitalized, 41% were hospitalized once, and 49% were hospitalized Ͼ2 times, for CHF, over five years. These proportions in patients with PSF were 24%, 51%, and 25%, respectively. Patients with reduced systolic function had significantly more hospitalizations.
The CHS also reported the risk of nonfatal MI and stroke (44) . In subjects with no CHF and PSF these rates were 10.9 and 12.5, respectively, per 1,000 patient-years at risk. The rates increased to 23.3 and 27.5 in patients with CHF and PSF, 37.7 and 50.7 in those with CHF and borderline systolic function, but fell again to 19.4 and 45.2, respectively, per 1,000 patient-years, in subjects with CHF and reduced systolic function. Even after adjustment in the Cox proportional hazards survival model, the risk of MI and (22) . In a multivariate analysis, however, reduced systolic function (compared to PSF) was not an independent predictor of hospitalization (whereas it was for death).
It is important to note that readmission rates in patients with PSF are very high-15% to 25% of patients are readmitted within six months and a third within a year with an exacerbation of CHF (and about 45% to 60% at one year for any reason).
It is clear that both types of CHF have a grim prognosis. Philbin et al. (26) showed that the six-month rate of death or readmission was 50% in patients with PSF and 52% in those with reduced systolic function.
REMAINING QUESTIONS
Many questions remain about the syndrome of HF-PSF. The proportion of such patients with valve disease has not been clearly defined in most studies. The higher prevalence of lung disease seen in patients with reduced systolic function raises the possibility of misdiagnosis, especially as HF-PSF is essentially a diagnosis of exclusion (4, 42) . Reliable non-invasive measures or markers of ventricular dysfunction are badly needed, but it is not clear whether natriuretic peptides will fulfill this need (45) . Similarly, the role of AF requires clarification. Is it AF that is the cause of CHF in many of these patients? Or does AF only precipitate CHF because of underlying DD?
The interaction between this type of CHF and AF is further confounded by evidence that DD is itself a predictor of future AF (23) . Also, why is HF-PSF more a problem for women than for men? As DD appears to be more common in men it would seem that the female left ventricle is less able to cope with DD. This is surprising given the more favorable remodeling changes seen in the overloaded female LV (46) . Indeed, the pathophysiology of this type of CHF remains poorly explained, and it may have as much to do with peripheral mechanisms as with cardiac dysfunction (47) . The greatest question of all, of course, is how to treat these patients. Symptom control is important. However, the finding from the CHS that the population-attributable risk for deaths from CHF is greater for PSF than for reduced systolic function emphasizes the public health imperative of developing treatments to reduce mortality (and morbidity) in these patients (48 -50) .
The CHARM-Preserved trial (using the ARB candesartan) showed that candesartan reduced the risk of hospital admission for worsening heart failure but did not affect mortality. Other outcome studies with an ARB, ACE inhibitor, and beta-blocker are ongoing (48 -50) . From a pathophysiological basis, it would also be of interest to study an aldosterone antagonist in this syndrome (6 -8) . Unfortunately, no study to date has provided detailed data on the causes of death in patients with HF-PSF, information that should be of value in the development and testing of treatments for this type of CHF.
